Name: 글로벌 시장 동향
SKU: PH3374
Availability: InStock

보고서 요약(국문)

보고서 개요
전 세계 편평세포 비소세포폐암 치료제 시장은 2023년 40억 달러 규모에 달했으며, 2024년부터 2031년까지 연평균 9.4% 성장하여 2031년에는 80억 6천만 달러에 이를 것으로 예상됩니다.
편평세포폐암은 비소세포폐암(NSCLC)의 일종입니다. 편평세포 폐종양은 주로 폐의 중심부 또는 주요 기도, 예를 들어 좌측 또는 우측 기관지에서 발생합니다. 세포 변형의 주요 원인은 흡연입니다. 남성 폐암 환자의 약 80%, 여성 폐암 환자의 약 90%가 흡연과 관련이 있습니다.
편평세포폐암은 다른 유형의 비소세포폐암보다 흡연과의 연관성이 훨씬 강합니다. 폐 편평세포암의 다른 위험 요인으로는 연령, 가족력, 간접흡연 노출, 광물, 금속 입자 또는 석면에 대한 직업적 노출 등이 있습니다. 비소세포폐암의 임상 증상으로는 기침, 흉통, 호흡곤란, 객혈, 천명, 쉰 목소리, 재발성 흉부 감염, 체중 감소, 식욕 부진, 피로 등이 있습니다.
시장 동향: 성장 동인
비소세포폐 편평세포암 발병률 증가
전 세계 비소세포폐 편평세포암 치료제 시장의 수요는 여러 요인에 의해 주도되고 있습니다. 비소세포폐 편평세포암 발병률의 증가가 시장 성장을 견인하고 있습니다.

예를 들어, 2024년 2월 nih.gov에 발표된 기사에 따르면, 미국 국립암연구소(NCI)의 감시 역학 및 결과(SEER) 데이터베이스에 따르면 2023년 폐암은 발생률 기준으로 미국에서 세 번째로 흔한 암이었으며, 암 관련 사망의 가장 흔한 원인이었습니다.
폐암 발생 건수는 238,340건으로 추산되었으며, 이는 미국 전체 암 부담의 12%를 차지했습니다. 2023년 폐암으로 인한 사망자는 127,070명으로 추산되었으며, 이는 미국 전체 암 관련 사망자의 약 21%에 해당합니다. 모든 폐암의 약 85%는 비소세포폐암(NSCLC)입니다. 선암과 편평세포암이 가장 흔한 아형으로, 각각 NSCLC 사례의 50%와 30%를 차지합니다.

제약 요인
치료제 관련 부작용, 높은 치료 비용, 신약 승인을 위한 엄격한 규제 요건 등의 요인이 시장 성장을 저해할 것으로 예상됩니다.
시장 세분화 분석
전 세계 편평 비소세포 폐암 치료제 시장은 치료 유형, 최종 사용자 및 지역별로 세분화됩니다.
화학 요법 부문은 전 세계 편평 비소세포 폐암 치료제 시장 점유율의 약 49.5%를 차지했습니다.
화학 요법 부문은 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 이 부문에서는 기술 발전과 민간 제조업체의 임상 시험 자금 증가가 시장 성장을 견인할 것입니다.
예를 들어, 2024년 2월에는 진행성 편평 비소세포 폐암 치료를 위한 신틸리맙과 2주기 화학 요법 병용 요법의 2상 임상 시험이 진행되었습니다. 본 연구는 진행성 편평 비소세포 폐암(sq-NSCLC) 환자를 대상으로 나브-파클리탁셀/카보플라틴 및 신틸리맙(항PD-1) 2주기 투여 후 신틸리맙 유지 요법을 시행한 단일군, 다기관 2상 임상시험(ChiCTR1900021726)입니다. 무진행 생존기간(PFS) 중앙값은 11.4개월(95% CI: 6.7-18.1)로, 사전에 설정된 1차 평가변수를 충족했습니다.
2차 평가변수로는 객관적 반응률 70.5%, 질병 조절률 93.2%가 있었으며, 반응 지속기간 중앙값은 13.6개월이었습니다. 전체 생존기간 중앙값은 27.2개월이었고, 치료 관련 이상반응 3등급 이상은 환자의 10.9%에서 발생했습니다. 사전에 정의된 탐색적 평가변수에는 바이오마커와 치료 효과 간의 관계, 그리고 순환 종양 DNA(ctDNA) 역학과 무진행 생존기간(PFS) 간의 연관성이 포함되었습니다.
시장 지역별 점유율
북미는 전 세계 편평 비소세포 폐암 치료제 시장의 약 42.8%를 차지했습니다.
북미 지역은 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 이 지역에서 편평 비소세포 폐암 발병률이 증가하고 있으며, 사람들의 인식이 높아지고 있는 것이 시장 성장을 견인하고 있습니다.
예를 들어, 2024년 1월 cancer.org에 발표된 기사에 따르면, 폐암(소세포 및 비소세포 모두)은 미국에서 남녀 모두에게 두 번째로 흔한 암입니다. 미국 암 협회는 2024년 미국 내 폐암 신규 발생 건수를 약 234,580건(남성 116,310건, 여성 118,270건)으로, 폐암으로 인한 사망자 수를 약 125,070명(남성 65,790명, 여성 59,280명)으로 추산했습니다.
남성이 평생 동안 폐암에 걸릴 확률은 약 16분의 1이고, 여성은 약 17분의 1입니다. 이 수치는 흡연자와 비흡연자 모두를 포함합니다. 흡연자의 경우 위험도가 훨씬 높고, 비흡연자의 경우 위험도가 낮습니다.

시장 세분화
치료 유형별
표적 치료
면역 요법
화학 요법
기타
최종 사용자별
병원
전문 클리닉
기타
지역별
북미
미국
캐나다
멕시코
유럽
독일
영국
프랑스
스페인
이탈리아
기타 유럽 지역
남미
브라질
아르헨티나
기타 남미 지역
아시아 태평양
중국
인도
일본
한국
기타 아시아 태평양 지역
중동 및 아프리카
시장 경쟁 환경
전 세계 편평 비소세포 폐암 치료제 시장의 주요 기업으로는 Genentech, Bristol Myers Squibb, Eli Lilly and Company, AstraZeneca, Pfizer Inc., Novartis AG, Merck Sharp & Dhome Corporation, Breckenridge Pharmaceutical Inc., Teva Pharmaceuticals 등이 있습니다. Inc., Apotex Corporation 등이 참여했습니다.
주요 개발 사항
2024년 1월, 쑨얏센대학교 암센터에서 PD-1 및 CTLA-4에 대한 이중 기능성 MabPair 제품인 QL1706과 화학요법 병용 투여의 안전성 및 효능을 조사하기 위한 다중 코호트 2상 연구(NCT05329025)를 진행했습니다. 이 연구에서는 EGFR 야생형 진행성 비소세포폐암 환자를 대상으로 QL1706과 화학요법 병용 투여는 베바시주맙 병용 여부와 관계없이 전반적으로 내약성이 양호했으며, 1차 치료 환경에서 유망한 항종양 활성을 보였습니다. 또한, QL1706과 화학요법 병용 투여는 EGFR 변이형 비소세포폐암 환자에서도 우수한 항종양 활성을 나타냈습니다.
2023년 11월, GSK Plc에서 PERLA 2상 임상시험을 진행했습니다. 1차 평가변수는 전체 반응률이었습니다. DCT는 PCT와 유사한 효능을 보였으며, 전이성 비편평세포 비소세포폐암 환자의 1차 치료제로서 임상적 효능을 입증했습니다.
2024년 2월, 백금 기반 이중 약물 1차 항암화학요법은 진행성 비소세포폐암(NSCLC) 환자 치료에 흔히 사용되지만, 임상적 효능은 제한적입니다. 베바시주맙은 혈관 내피세포 성장인자(VEGF)를 억제하여 종양 혈관신생을 저해하고 종양 침윤 및 발달을 예방합니다. (중국 과학기술대학교 연구진 발표) 베바시주맙을 포함한 병용요법은 단독 항암화학요법에 비해 향상된 항종양 효과를 보였습니다.
보고서 구매 이유:
치료 유형, 최종 사용자 및 지역별 글로벌 비소세포폐암 치료제 시장 세분화를 시각화하고 주요 상업적 자산 및 기업을 파악하기 위함입니다.

트렌드 분석 및 공동 개발을 통해 상업적 기회를 파악하세요.
모든 세그먼트를 포함한 글로벌 편평 비소세포 폐암 치료제 시장의 다양한 데이터 포인트가 담긴 엑셀 데이터 시트가 제공됩니다.
PDF 보고서는 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석 결과를 담고 있습니다.
모든 주요 기업의 핵심 제품을 포함하는 제품 매핑은 엑셀 파일로 제공됩니다.
글로벌 편평 비소세포 폐암 치료제 시장 보고서는 약 51개의 표, 54개의 그림, 181페이지 분량입니다.
대상 고객 (2024년 기준)
제조업체/구매자
산업 투자자/투자 은행가
연구 전문가
신흥 기업

보고서 요약(영어 원문)

Report Overview
The Global Squamous Non-Small Cell Lung Cancer Therapeutics Market reached US$4 billion in 2023 and is expected to reach US$ 8.06 billion by 2031, growing at a CAGR of 9.4% during the forecast period 2024-2031.
Squamous cell carcinoma of the lung, also known as squamous cell lung cancer, is a type of non-small cell lung cancer (NSCLC). Squamous cell lung tumors often occur in the central part of the lung or the main airway, such as the left or right bronchus. The principal causative agent of cellular transformation is smoking. Approximately 80% of lung cancer cases in men and 90% of patients in women are associated with smoking.
SCC is more strongly associated with smoking than any other type of NSCLC. Other risk factors for squamous cell carcinoma of the lung include age, family history, exposure to second-hand smoke, and occupational exposure to minerals, metal particles, or asbestos. Clinical symptoms of NSCLCs include cough, chest pain, shortness of breath, blood in sputum, wheezing, hoarseness, recurring chest infections weight loss, loss of appetite, and fatigue.
Market Dynamics: Drivers
Increasing prevalence of squamous non-small cell lung cancer
The demand for the global squamous non-small cell lung cancer therapeutics market is driven by multiple factors. The rising prevalence of squamous non-small cell lung cancer propels the market growth.
For instance, according to an article published by nih.gov in February 2024, in 2023, lung cancer was the third most common cancer in terms of incidence and the most common cause of cancer-related mortality in the US, as per the National Cancer Institute's Surveillance Epidemiology and End Results database.
Lung cancer incidence was estimated at 238,340 cases, accounting for 12% of the cancer burden in the US. The estimated mortality for lung cancer in 2023 was 127,070 deaths, constituting around 21% of all US cancer-related deaths. Approximately 85% of all lung cancers are NSCLCs. Adenocarcinoma and squamous cell carcinoma are the most common subtypes, accounting for 50% and 30% of NSCLC cases, respectively.
Restraints
Factors such as side effects associated with therapeutic drugs, high costs associated with the treatment, and stringent regulatory requirements for the approval of new therapies are expected to hamper the market.
Market Segment Analysis
The global squamous non-small cell lung cancer therapeutics market is segmented based on therapy type, end-user, and region.
The segment chemotherapy accounted for approximately 49.5% of the global squamous non-small cell lung cancer therapeutics market share
The chemotherapy segment is expected to hold the largest market share over the forecast period. In this segment, technological advancements, and rising funds for private manufacturers for clinical trials would drive this market.
For instance, in February 2024, the phase 2 clinical trials of sintilimab with two cycles of chemotherapy for the treatment of advanced squamous non-small cell lung cancer is performed. This was a single-arm, multicenter phase 2 clinical trial (ChiCTR1900021726) involving advanced squamous non-small cell lung cancer (sq-NSCLC) patients undergoing 2 cycles of nab-paclitaxel/carboplatin and sintilimab (anti-PD-1), followed by sintilimab maintenance therapy. The median progression-free survival (PFS) was 11.4 months (95% CI: 6.7-18.1), which met the pre-specified primary endpoint.
Secondary endpoints included an objective response rate reaching 70.5% and a disease control rate of 93.2%, with a median duration of response of 13.6 months. The median overall survival was 27.2 months with treatment-related adverse events grades ≥3 occurring in 10.9% of patients. Predefined exploratory endpoints comprised relationships between biomarkers and treatment efficacy, and the association between circulating tumor DNA (ctDNA) dynamics and PFS.
Market Geographical Share
North America accounted for approximately 42.8% of the global squamous non-small cell lung cancer therapeutics market market share
North America region is expected to hold the largest market share over the forecast period. The rising incidence of squamous non-small cell lung cancer, and growing awareness among people, in this region, help to propel the market.
For instance, according to an article published by cancer.org in January 2024, Lung cancer (both small cell and non-small cell) is the second most common cancer in both men and women in the United States. The American Cancer Society’s estimates for lung cancer in the US for 2024 are about 234,580 new cases of lung cancer (116,310 in men and 118,270 in women) and about 125,070 deaths from lung cancer (65,790 in men and 59,280 in women).
The chance that a man will develop lung cancer in his lifetime is about 1 in 16; for a woman, the risk is about 1 in 17. These numbers include both people who smoke and those who don’t smoke. For people who smoke, the risk is much higher, while for those who don't, the risk is lower.
Market Segmentation
By Therapy Type
Targeted Therapy
Immunotherapy
Chemotherapy
Others
By End-User
Hospitals
Specialty Clinics
Others
By Region
North America
The U.S.
Canada
Mexico
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
South America
Brazil
Argentina
Rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa
Market Competitive Landscape
The major global players in the global squamous non-small cell lung cancer therapeutics market include Genentech, Bristol Myers Squibb, Eli Lilly and Company, AstraZeneca, Pfizer Inc., Novartis AG, Merck Sharp & Dhome Corporation, Breckenridge Pharmaceutical Inc., Teva Pharmaceuticals Inc., Apotex Corporation among others.
Key Developments
In January 2024, a multi-cohort phase II study (NCT05329025) was done by Sun Yat-sen University Cancer Center to investigate the safety and efficacy of QL1706 (a single bifunctional MabPair product against PD-1 and CTLA-4) and chemotherapy with or without bevacizumab in this population. Overall, QL1706 plus chemotherapy, regardless of having bevacizumab, was generally tolerable and had promising antitumor activity for EGFR wild-type advanced NSCLC in a first-line setting. Moreover, QL1706 plus chemotherapy and bevacizumab showed favorable antitumor activity for patients who had EGFR-mutated NSCLC.
In November 2023, the PERLA phase 2 trials were performed by GSK Plc. The primary endpoint was the overall response rate. The DCT showed similar efficacy to PCT and demonstrates clinical efficacy as a first-line treatment for patients with metastatic non-squamous NSCLC.
In February 2024, Platinum-based dual-drug first-line chemotherapy is commonly employed in the treatment of patients with advanced non-small cell lung cancer (NSCLC), although its clinical efficacy is limited. Bevacizumab can antagonize vascular endothelial cell growth factor (VEGF), which inhibits tumor angiogenesis and prevents tumor invasion and development in the University of Science and Technology, China. Combination therapy involving bevacizumab demonstrated improved antitumor effects compared to chemotherapy alone.
Why Purchase the Report?
To visualize the global squamous non-small cell lung cancer therapeutics market segmentation based on therapy type, end-user, and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development
Excel data sheet with numerous data points of global squamous non-small cell lung cancer therapeutics market level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in Excel consisting of key products of all the major players.
The global squamous non-small cell lung cancer therapeutics market report would provide approximately 51 tables, 54 figures, and 181 Pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Therapy Type
3.2. Snippet by End-User
3.3. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of Squamous Non-Small Cell Lung Cancer
4.1.1.2. Technological Advancements
4.1.1.3. Allotment of Funding for Research Works
4.1.2. Restraints
4.1.2.1. Side Effects Associated with Therapeutic Drugs
4.1.2.2. High Cost Associated with the Treatment
4.1.2.3. Stringent Regulatory Requirements
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
6. By Therapy Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
6.1.2. Market Attractiveness Index, By Therapy Type
6.2. Targeted Therapy*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Immunotherapy
6.4. Chemotherapy
6.5. Others
6.6. infection
6.7. Others
7. By End-User
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
7.1.2. Market Attractiveness Index, By End-User
7.2. Hospitals*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Specialty Clinics
7.4. Others
8. By Region
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.5.1. The U.S.
8.2.5.2. Canada
8.2.5.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.5.1. Germany
8.3.5.2. UK
8.3.5.3. France
8.3.5.4. Italy
8.3.5.5. Spain
8.3.5.6. Rest of Europe
8.4. South America
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.5.1. Brazil
8.4.5.2. Argentina
8.4.5.3. Rest of South America
8.5. Asia-Pacific
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.5.1. China
8.5.5.2. India
8.5.5.3. Japan
8.5.5.4. South Korea
8.5.5.5. Rest of Asia-Pacific
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9. Competitive Landscape
9.1. Competitive Scenario
9.2. Market Positioning/Share Analysis
9.3. Mergers and Acquisitions Analysis
10. Company Profiles
10.1. Genentech *
10.1.1. Company Overview
10.1.2. Product Portfolio and Description
10.1.3. Financial Overview
10.1.4. Key Developments
10.2. Bristol Myers Squibb
10.3. Eli Lilly and Company
10.4. AstraZeneca
10.5. Pfizer Inc.
10.6. Novartis AG
10.7. Merch Sharp & Dhome Corporation
10.8. Breckenridge Pharmaceuticals Inc.
10.9. Teva Pharmaceuticals Inc.
10.10. Apotex Corporation (*LIST NOT EXHAUSTIVE)
11. Appendix
11.1. About Us and Services
11.2. Contact Us

언급된 주요 기업들

Genentech, 4.	Key Developments, Bristol Myers Squibb, Eli Lilly and Company, AstraZeneca, Pfizer Inc., Novartis AG, Merch Sharp & Dhome Corporation, Breckenridge Pharmaceuticals Inc., Teva Pharmaceuticals Inc.

표 목록 (Tables)

List of Tables

Table 1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Value, By Therapy Type, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Value, By End-User, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Value, By Therapy Type, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Value, By Therapy Type, 2022-2031 (US$ Million)

Table 6 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Value, By End-User, 2023, 2027 & 2031 (US$ Million)

Table 7 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Value, By End-User, 2022-2031 (US$ Million)

Table 8 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 9 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Value, By Region, 2022-2031 (US$ Million)

Table 10 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Value, By Therapy Type, 2022-2031 (US$ Million)

Table 11 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Value, By End-User, 2022-2031 (US$ Million)

Table 12 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Value, By Country, 2022-2031 (US$ Million)

Table 13 South America Squamous Non-Small Cell Lung Cancer Therapeutics Market Value, By Therapy Type, 2022-2031 (US$ Million)

Table 14 South America Squamous Non-Small Cell Lung Cancer Therapeutics Market Value, By End-User, 2022-2031 (US$ Million)

Table 15 South America Squamous Non-Small Cell Lung Cancer Therapeutics Market Value, By Country, 2022-2031 (US$ Million)

Table 16 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Value, By Therapy Type, 2022-2031 (US$ Million)

Table 17 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Value, By End-User, 2022-2031 (US$ Million)

Table 18 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Value, By Country, 2022-2031 (US$ Million)

Table 19 Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Value, By Therapy Type, 2022-2031 (US$ Million)

Table 20 Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Value, By End-User, 2022-2031 (US$ Million)

Table 21 Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Value, By Country, 2022-2031 (US$ Million)

Table 22 Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Value, By Therapy Type, 2022-2031 (US$ Million)

Table 23 Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Value, By End-User, 2022-2031 (US$ Million)

Table 24 Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Value, By Country, 2022-2031 (US$ Million)

Table 25 Genentech: Overview

Table 26 Genentech: Product Portfolio

Table 27 Genentech: Key Developments

Table 28 Bristol Myers Squibb: Overview

Table 29 Bristol Myers Squibb: Product Portfolio

Table 30 Bristol Myers Squibb: Key Developments

Table 31 Eli Lilly and Company: Overview

Table 32 Eli Lilly and Company: Product Portfolio

Table 33 Eli Lilly and Company: Key Developments

Table 34 AstraZeneca: Overview

Table 35 AstraZeneca: Product Portfolio

Table 36 AstraZeneca: Key Developments

Table 37 Pfizer Inc.: Overview

Table 38 Pfizer Inc.: Product Portfolio

Table 39 Pfizer Inc.: Key Developments

Table 40 Novartis AG: Overview

Table 41 Novartis AG: Product Portfolio

Table 42 Novartis AG: Key Developments

Table 43 Merck Sharp & Dhome Corporation: Overview

Table 44 Merck Sharp & Dhome Corporation: Product Portfolio

Table 45 Merck Sharp & Dhome Corporation: Key Developments

Table 46 Breckenridge Pharmaceutical Inc.: Overview

Table 47 Breckenridge Pharmaceutical Inc.: Product Portfolio

Table 48 Breckenridge Pharmaceutical Inc.: Key Developments

Table 49 Teva Pharmaceuticals Inc.: Overview

Table 50 Teva Pharmaceuticals Inc.: Product Portfolio

Table 51 Teva Pharmaceuticals Inc.: Key Developments

Table 52 Apotex Corporation: Overview

Table 53 Apotex Corporation: Product Portfolio

Table 54 Apotex Corporation: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Value, 2022-2031 (US$ Million)

Figure 2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share, By Therapy Type, 2023 & 2031 (%)

Figure 3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share, By End-User, 2023 & 2031 (%)

Figure 4 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share, By Region, 2023 & 2031 (%)

Figure 5 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Y-o-Y Growth, By Therapy Type, 2023-2031 (%)

Figure 6 Targeted Therapy Squamous Non-Small Cell Lung Cancer Therapeutics Market Value, 2022-2031 (US$ Million)

Figure 7 Immunotherapy Squamous Non-Small Cell Lung Cancer Therapeutics Market Value, 2022-2031 (US$ Million)

Figure 8 Chemotherapy Squamous Non-Small Cell Lung Cancer Therapeutics Market Value, 2022-2031 (US$ Million)

Figure 9 Others Squamous Non-Small Cell Lung Cancer Therapeutics Market Value, 2022-2031 (US$ Million)

Figure 10 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Y-o-Y Growth, By End-User, 2023-2031 (%)

Figure 11 Hospitals End-User in Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Value, 2022-2031 (US$ Million)

Figure 12 Specialty Clinics End-User in Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Value, 2022-2031 (US$ Million)

Figure 13 Others End-User in Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Value, 2022-2031 (US$ Million)

Figure 14 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Y-o-Y Growth, By Region, 2023-2031 (%)

Figure 15 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Value, 2022-2031 (US$ Million)

Figure 16 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Share, By Therapy Type, 2023 & 2031 (%)

Figure 17 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Share, By End-User, 2023 & 2031 (%)

Figure 18 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Share, By Country, 2023 & 2031 (%)

Figure 19 South America Squamous Non-Small Cell Lung Cancer Therapeutics Market Value, 2022-2031 (US$ Million)

Figure 20 South America Squamous Non-Small Cell Lung Cancer Therapeutics Market Share, By Therapy Type, 2023 & 2031 (%)

Figure 21 South America Squamous Non-Small Cell Lung Cancer Therapeutics Market Share, By End-User, 2023 & 2031 (%)

Figure 22 South America Squamous Non-Small Cell Lung Cancer Therapeutics Market Share, By Country, 2023 & 2031 (%)

Figure 23 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Value, 2022-2031 (US$ Million)

Figure 24 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Share, By Therapy Type, 2023 & 2031 (%)

Figure 25 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Share, By End-User, 2023 & 2031 (%)

Figure 26 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Share, By Country, 2023 & 2031 (%)

Figure 27 Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Value, 2022-2031 (US$ Million)

Figure 28 Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Share, By Therapy Type, 2023 & 2031 (%)

Figure 29 Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Share, By End-User, 2023 & 2031 (%)

Figure 30 Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Share, By Country, 2023 & 2031 (%)

Figure 31 Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Value, 2022-2031 (US$ Million)

Figure 32 Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Share, By Therapy Type, 2023 & 2031 (%)

Figure 33 Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Share, By End-User, 2023 & 2031 (%)

Figure 34 Genentech: Financials

Figure 35 Bristol Myers Squibb: Financials

Figure 36 Eli Lilly and Company: Financials

Figure 37 AstraZeneca: Financials

Figure 38 Pfizer Inc.: Financials

Figure 39 Novartis AG: Financials

Figure 40 Merck Sharp & Dhome Corporation: Financials

Figure 41 Breckenridge Pharmaceutical Inc.: Financials

Figure 42 Teva Pharmaceuticals Inc.: Financials

Figure 43 Apotex Corporation: Financials

2024년부터 2031년까지 전 세계 편평 비소세포 폐암 치료제 시장 전망

Global Squamous Non-Small Cell Lung Cancer Therapeutics Market - 2024 - 2031